News

Robotic Ribosome
Enlarge image

ResearchUK

Robotic Ribosome

11.01.2013 - Researches have constructed the first molecular machine that can produce peptides of defined sequences in milligram quantities.

The group of Bartosz Lewandowski from University of Manchester have taken another step toward the creation of a synthetic machine that performs the duties of a ribosome, which builds proteins in living organisms by joining amino acids together. As reported in Science, they have designed an artificial small-molecule machine that travels along a molecular strand, picking up amino acids that block its path, to synthesise a peptide in a sequence-specific manner.

The chemical structure is based on a rotaxane, a molecular ring threaded onto a molecular axle. The ring carries a thiolate group that iteratively removes amino acids in order from the strand and transfers them to a peptide-elongation site through native chemical ligation. The synthesis was demonstrated with ~1018 molecular machines acting in parallel; this process generated milligram quantities of a peptide with a single sequence confirmed by tandem mass spectrometry.

The study demonstrates that, in principle, small artificial molecular machines can be designed to perform such tasks autonomously. However, their machine lacked performance. In the current lab setting it only joined 3 amino acids together.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/robotic-ribosome.html

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC5.41 EUR4.04%
  • WILEX5.25 EUR3.35%
  • BIOFRONTERA2.34 EUR1.74%

FLOP

  • VITA 345.86 EUR-6.69%
  • FORMYCON26.31 EUR-6.04%
  • MORPHOSYS63.42 EUR-6.02%

TOP

  • 4SC5.41 EUR263.1%
  • WILEX5.25 EUR72.1%
  • SARTORIUS148.50 EUR15.7%

FLOP

  • BIOTEST72.00 EUR-24.1%
  • THERAMETRICS0.07 CHF-22.2%
  • MERCK KGAA96.29 EUR-10.9%

TOP

  • SANTHERA96.00 CHF2361.5%
  • CYTOS1.27 CHF807.1%
  • WILEX5.25 EUR510.5%

FLOP

  • MOLOGEN4.85 EUR-55.9%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.34 EUR-27.8%

No liability assumed, Date: 06.05.2015